Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2.2

ISSN Imprimer: 0893-9675
ISSN En ligne: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.2013007921
pages 409-434

Iron Chelation: Inhibition of Key Signaling Pathways in the Induction of the Epithelial Mesenchymal Transition in Pancreatic Cancer and Other Tumors

Alexander Richardson
Iron Metabolism and Chelation Program, Department of Pathology and Bosch Institute, University of Sydney, Sydney, New South Wales, 2006, Australia
Zaklina Kovacevic
Iron Metabolism and Chelation Program, Department of Pathology and Bosch Institute, University of Sydney, Sydney, New South Wales, 2006, Australia
Des R. Richardson
Iron Metabolism and Chelation Program, Department of Pathology and Bosch Institute, University of Sydney, Sydney, New South Wales, 2006, Australia

RÉSUMÉ

Pancreatic cancer is the fourth leading cause of cancer-related deaths worldwide in both men and women. It presents late with non-specific symptoms, which makes it difficult to diagnose until the cancer has progressed and metastasized. Metastasis is facilitated by the epithelial-to-mes-enchymal transition (EMT), which is promoted via the oncogenic transforming growth factor beta (TGFβ), Wnt, and nuclear factor kappa B (NFκB) signaling pathways. However, recent studies have demonstrated that the EMT can be inhibited by novel anti-cancer agents known as thiosemicarbazone iron chelators. These novel agents also up-regulate the metastasis suppressor, N-myc downstream regulated gene 1 (NDRG1), which can restore normal signaling to the cell and suppresses metastasis via inhibition of the EMT. Through the ability of iron chelators to up-regulate NDRG1 expression and affect multiple molecular targets, these agents have the potential to maintain the epithelial phenotype of cancer cells and may lead to improved survival rates for patients with late-stage disease.


Articles with similar content:

A New Linkage between the Tumor Suppressor RKIP and Autophagy: Targeted Therapeutics
Critical Reviews™ in Oncogenesis, Vol.23, 2018, issue 5-6
Yuhao Wang, Benjamin Bonavida
Epithelial-Mesenchymal Transition: A Special Focus on Phthalates and Bisphenol A
Journal of Environmental Pathology, Toxicology and Oncology, Vol.35, 2016, issue 1
Belmar Kocer-Gumusel, Ming-Wei Chao, Didem Oral, Pinar Erkekoglu
Molecular Mechanisms Underlying the Role of MicroRNAs in Resistance to Epidermal Growth Factor Receptor-Targeted Agents and Novel Therapeutic Strategies for Treatment of Non-Small-Cell Lung Cancer
Critical Reviews™ in Oncogenesis, Vol.18, 2013, issue 4
Elena Galvani, Godefridus J. Peters, Mina Maftouh, Elisa Giovannetti, Amir Avan
Role of GLI1 and NDRG1 in Increased Resistance to Apoptosis Induction
Journal of Environmental Pathology, Toxicology and Oncology, Vol.34, 2015, issue 3
William N. Rom, Yukio Hosomi, Kam-Meng Tchou-Wong, Minori Koshiji, Yiqun Mo, Feng Wu
Roles of Smad3 in TGF-β Signaling During Carcinogenesis
Critical Reviews™ in Eukaryotic Gene Expression, Vol.17, 2007, issue 4
Caroline Millet, Ying E. Zhang